Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $30.29, but opened at $31.70. Supernus Pharmaceuticals shares last traded at $30.71, with a volume of 27,147 shares trading hands.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on SUPN. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th.
Check Out Our Latest Analysis on SUPN
Supernus Pharmaceuticals Price Performance
The stock has a market capitalization of $1.80 billion, a P/E ratio of 30.11 and a beta of 0.90. The stock has a fifty day moving average price of $31.94 and a 200 day moving average price of $34.99.
Insider Buying and Selling at Supernus Pharmaceuticals
In other news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 in the last quarter. 9.30% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Supernus Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Barclays PLC grew its position in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after purchasing an additional 2,121 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 5.4% in the 3rd quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company's stock worth $8,899,000 after purchasing an additional 14,566 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after buying an additional 73,118 shares in the last quarter. Finally, Burney Co. lifted its position in Supernus Pharmaceuticals by 603.4% in the 4th quarter. Burney Co. now owns 83,152 shares of the specialty pharmaceutical company's stock worth $3,007,000 after buying an additional 71,331 shares during the last quarter.
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
